<DOC>
	<DOC>NCT00787293</DOC>
	<brief_summary>Improvement in heart failure with moderate to severe mitral regurgitation using a percutaneously delivered implantable device.</brief_summary>
	<brief_title>Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Functional MR 2+ 4+ Symptomatic heart failure, NYHA Class II to IV LVEF &gt; 25% or &lt; 50% OR dilated mitral annulus &gt; 30mm MR of organic origin Severe mitral leaflet tethering History of MI or PCI within 60 days of study procedure Inability to walk a minimum of 100 meters in 6 minutes Significant left main stenosis or proximal circumflex stent Indication of nonpatent CSO or discontinuous CSGCVAIV Biventricular with leads in CS or other devices impeding device placement Severe aortic valvular disease Chronic corticosteroid use other than &lt; 20mg prednisone for arthritis Significant comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>Percutaneous</keyword>
	<keyword>Coronary sinus</keyword>
</DOC>